France’s First Ever Hobby Shop Focused on GUNPLA: BANDAI HOBBY STORE
27.7.2020 10:00:00 EEST | Business Wire | Press release
BANDAI S.A.S. (President & CEO: Susumu Hirasawa; Head office: Tour W 102, Terrasse Boieldieu 92085 Paris La Defense cedex France) of the BANDAI NAMCO Group, Manga Story SARL (President & CEO: Patrick Carosella; Head office: 13 Boulevard Voltaire, 75011 Paris, France), and BANDAI SPIRITS CO., LTD. (President & CEO: Yusuke Fukuda; Head office: Minato-ku, Tokyo) will open the BANDAI HOBBY STORE, France's first ever hobby shop centered around GUNPLA, in the central Republic district of Paris, France on July 30, 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200727005200/en/
BANDAI HOBBY STORE interior image. It may differ in part from the actual site. (C)SOTSU・SUNRISE
The aim of the BANDAI HOBBY STORE is to expand the BANDAI SPIRITS plastic model business in Europe by offering Europe's largest selection of GUNPLA. In addition to GUNPLA and GUNDAM-related products from the BANDAI NAMCO Group, the store will also offer many other plastic models, etc. from BANDAI SPIRITS.
The central Republic district where the new store will open is home to multiple shops selling games, anime, and comics, attracting users from all around France. Manga Story, the largest shop in the area, began selling BANDAI plastic models, focused on GUNPLA, around four years ago. Discussions with the president, Mr. Carosella regarding the possibility of opening a shop specializing in plastic models had been ongoing for some time, leading to the opening of this new store in the same area.
With about 200 square meters of space on the main floor and in the basement, the store will carry about 600 different types of plastic models, including both new and conventional products. With the various GUNPLA categories organized by color for ease of understanding, and a workshop area at the back of the store where customers can try assembling the models, everyone from child to adult, beginner to expert, will find a variety of ways to enjoy plastic models, from hands-on experience to purchase.
We will use the opening of this store as an opportunity to explore the possibility of opening multiple stores in the future.
|
Store Overview |
|
|
Name: |
BANDAI HOBBY STORE |
|
Location: |
5 boulevard Voltaire, 75011 Paris, France |
|
Business hours: |
Monday-Saturday 10:00-19:30 Closed Sundays |
|
Store area: |
Approximately 200 m2 |
|
Management: |
Manga Story |
|
Admission: |
Free |
What is "GUNPLA"?
GUNPLA are plastic models based on the GUNDAM series, launched in Japan in July 1980 and celebrating their 40th anniversary this year. So far, over 700 million units have been sold: 525.8 million from the Real series, and 174.4 million from the SD series (as of the end of May 2020), making GUNPLA the biggest hit in the history of plastic models. In recent years, we have been growing our overseas market.
Image download URL: https://bit.ly/ (this URL is valid for 30 days from the date of distribution)
* The information in this press release is current as of July 27, 2020, and is subject to change without notice.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200727005200/en/
Contact information
Press inquiries:
BANDAI S.A.S. Makoto Nishiyama (mnishiyama@bandai.fr)
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom